Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

These metabolic alterations could help explain the neurological symptoms of Dravet syndrome, like seizures and developmental delays, which require large amounts of energy in the brain.

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

New research from the University of Colorado Anschutz Medical Campus is the first to identify defects related to metabolism (how the body processes and uses energy) in lymphoblast cell lines (LCLs) ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share price.

A recent study led by the UAB demonstrates the potential of gene therapy to restore motor capacity in an ultra-rare disease, ...

At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...